Q-linea AB (publ)
SSE:QLINEA.ST
2.49 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Q-linea AB (publ) |
Symbool | QLINEA.ST |
Munteenheid | SEK |
Prijs | 2.49 |
Beurswaarde | 290,925,445 |
Dividendpercentage | 0% |
52-weken bereik | 2.4 - 11.2 |
Industrie | Medical Instruments & Supplies |
Sector | Healthcare |
CEO | Dr. Jonas Jarvius Ph.D. |
Website | https://www.qlinea.com |
An error occurred while fetching data.
Over Q-linea AB (publ)
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)